Subscribe To

Price Alert Latest News Economic Calendar News

GLTO / Galecto shares drop 65% as biotech halts development of lung-disease treatment

Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease. After the treatment, GB0139, failed to meet its primary trial endpoint, Galecto said it will discontinue development and focus instead on treatments for severe liver diseases. Read More

Demo Live Account See Partner Details

Content Topics

Galecto

Drop

Biotech

Halts

Development

Lung

Disease

Lung disease

Treatment

Stock

GLTO

Posted: Aug 15 2023, 08:39

Author Name: Market Watch

GLTO News

By GlobeNewsWire
August 31, 2023

Galecto to Present at Investor Conferences in September

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology fo

By Zacks Investment Research
August 16, 2023

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.

By Market Watch
August 15, 2023

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idi

By Reuters
August 15, 2023

Galecto to discontinue development of lung disease treatment

Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid

By GuruFocus
July 27, 2023

ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc

On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnolo

By 24/7 Wall Street
April 10, 2023

Orbimed Advisors Now Owns 10.5% of Galecto

Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO).

By Zacks Investment Research
November 11, 2022

All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy

Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.